Product
Zandelisib
Aliases
ME-401, Zandelisib (ME-401)
3 clinical trials
4 indications
Indication
Follicular LymphomaIndication
Non-Hodgkin LymphomaIndication
Marginal Zone LymphomaIndication
Chronic Lymphocytic LeukemiaClinical trial
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL StudyStatus: Terminated, Estimated PCD: 2023-03-20
Clinical trial
A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)Status: Terminated, Estimated PCD: 2023-03-24
Clinical trial
A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL StudyStatus: Withdrawn, Estimated PCD: 2023-03-15